NVRO Nevro Corp

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 01, 2023

 

 

NEVRO CORP.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-36715	56-2568057
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1800 Bridge Parkway
Redwood City, California				94065
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 251-0005

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		NVRO		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On November 1, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and nine months ended September 30, 2023. The full text of the press release is furnished herewith as Exhibit 99.1.

---

The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press release dated November 1, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEVRO CORP.
Date:	November 1, 2023	By:	/s/ Roderick H. MacLeod
			Roderick H. MacLeod Chief Financial Officer

 

---

Exhibit 99.1

 

FOR IMMEDIATE RELEASE   Investors and Media:   Rod MacLeod, CFO Nevro Corp. ir@nevro.com   Greg Chodaczek Gilmartin Group LLC greg@gilmartinir.com

 

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

 

REDWOOD CITY, California – November 1, 2023 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third quarter 2023 financial results. The Company also provided fourth quarter guidance and updated its full-year 2023 guidance.

Recent Business Highlights and Guidance

Third Quarter 2023 Financial Overview

Worldwide revenue for the third quarter of 2023 was $103.9 million, an increase of 3% as reported and on a constant currency basis, compared to $100.5 million in the third quarter of 2022. PDN indication sales represented approximately $20.8 million and 20% of worldwide permanent implant procedures in the third quarter of 2023.

U.S. revenue in the third quarter of 2023 was $89.8 million, reflecting growth of 4% over $86.1 million in the third quarter of 2022. U.S. permanent implant procedures increased 7% compared to the third quarter of 2022, while U.S. trial procedures increased 4% compared to the third quarter of 2022. U.S. PDN trial

Page | 1

---

 

procedures represented approximately 24% of total U.S. trial volume and grew approximately 41% over the third quarter of 2022.

International revenue in the third quarter of 2023 was $14.1 million, compared to $14.3 million in the third quarter of 2022, a decrease of 2% as reported or a decrease of 6% on a constant currency basis.

"I am very pleased with our third quarter results. The changes and processes we put in place over the past five months are well underway, and we are beginning to experience the positive results from them," said Kevin Thornal, Nevro's CEO and President. "While we are encouraged by the early momentum we are experiencing, we know it will take several quarters for our financial results to fully reflect the positive changes we have made throughout the Company. We are excited about the opportunities ahead and delivering on our three core pillars: commercial execution, market penetration, and profit progress."

Gross profit for the third quarter of 2023 was $69.5 million, compared to $69.3 million in the third quarter of 2022. Gross margin was 66.9% in the third quarter of 2023, compared to 69.0% in the third quarter of 2022. "The full market release of the HFX iQ system continues to progress well. We are capturing a pricing uplift on our HFX iQ product, which is currently being offset by legacy product pricing pressures. We remain optimistic on our long run margin expansion opportunities with our Costa Rica sourced products." added Rod MacLeod, Chief Financial Officer.

Operating expenses for the third quarter of 2023 were $95.1 million, compared to $92.2 million in the third quarter of 2022, excluding $105.0 million of certain litigation credits in the third quarter of 2022. The increase in operating expenses was primarily due to litigation and personnel related costs, partially offset by a decrease in stock-based compensation. Litigation-related legal expenses were $4.3 million for the third quarter of 2023, compared to $1.9 million in the third quarter of 2022.

Net loss from operations for the third quarter of 2023 was $25.6 million, compared to net income of $82.1 million, or a loss of $22.9 million in the third quarter of 2022, excluding the $105.0 million of litigation-related credits. Non-GAAP adjusted EBITDA for the third quarter of 2023 was a loss of $5.8 million, compared to a loss of $3.8 million in the third quarter of 2022. Non-GAAP adjusted EBITDA excludes interest, taxes, and non-cash items such as stock-based compensation, depreciation and amortization, restructuring charges, litigation-related expenses, and certain litigation charges and credits. Please see the financial table below for GAAP to non-GAAP reconciliations.

Cash, cash equivalents, and short-term investments totaled $320.3 million as of September 30, 2023, a decrease of $9.7 million from June 30, 2023. This decrease was primarily driven by cash used in operations.

Fourth Quarter and Full-Year 2023 Guidance

Nevro expects fourth quarter of 2023 worldwide revenue of approximately $108 million to $110 million, or a decrease of 4% to 6% over prior year on a constant currency basis.

The Company expects fourth quarter of 2023 non-GAAP adjusted EBITDA to be a gain of approximately $1 million to $2 million. Non-GAAP adjusted EBITDA excludes interest, taxes, and non-cash items such as stock-based compensation and depreciation and amortization, as well as litigation-related expenses, certain litigation charges and credits and other adjustments such as restructuring charges. Please see the financial tables for GAAP to non-GAAP reconciliations.

The Company now expects full-year 2023 worldwide revenue of approximately $417 million to $419 million, an increase of 3% over prior year on both an as reported and constant currency basis. This compares to previous guidance of $410 million to $415 million.

The Company now expects full-year 2023 non-GAAP adjusted EBITDA to be a loss of approximately $24 million to $25 million, compared to previous guidance of a loss of $25 million to $28 million and a non-GAAP

Page | 2

 

---

 

adjusted EBITDA loss of $23.8 million in 2022. Please see the financial tables for GAAP to non-GAAP reconciliations.

An investor presentation for the Company's third quarter 2023 financial results is available in the "Investors" section of Nevro's website at www.nevro.com.

Webcast and Conference Call Information

As previously announced, Nevro management will host a conference call starting at 1:30 pm PT / 4:30 pm ET today. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using Conference ID: 3583097. A live webcast, as well as an archived recording, will also be available in the "Investors" section of Nevro's website at: www.nevro.com.

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The Company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.

Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements reflecting the Company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our fourth quarter and updated full-year 2023 financial guidance; our belief that it will take several quarters for our financial results to fully reflect the positive changes we have made throughout the Company; our belief that our three key pillars for our strategic focus will improve our commercial execution and deliver significant long-term shareholder return; and our belief in long run margin expansion opportunities with our Costa Rica sourced products. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet

Page | 3

 

---

 

demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to successfully integrate any additive acquisitions we may make; our ability to attract and retain qualified personnel; our ability to accurately forecast financial and operating results; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 21, 2023, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Nevro's operating results for the third quarter ended September 30, 2023 are not necessarily indicative of our operating results for any future periods.

 

Page | 4

 

---

 

Nevro Corp.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

 

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(unaudited)								(unaudited)
Revenue		$	103,862			$	100,466			$	308,998			$	292,521
Cost of revenue			34,346				31,164				100,415				91,393
Gross profit			69,516				69,302				208,583				201,128
Operating expenses:
Research and development			13,923				14,030				41,998				39,118
Sales, general and administrative			81,152				78,190				254,106				241,488
Certain litigation charges (credits)			—				(105,000	)			—				(105,000	)
Total operating expenses			95,075				(12,780	)			296,104				175,606
Income (loss) from operations			(25,559	)			82,082				(87,521	)			25,522
Other income (expense):
Interest income (expense), net			1,976				(480	)			5,371				(3,266	)
Other income (expense), net			234				391				(150	)			844
Income (loss) before income taxes			(23,349	)			81,993				(82,300	)			23,100
Provision for income taxes			130				485				932				907
Net income (loss)			(23,479	)			81,508				(83,232	)			22,193
Changes in foreign currency translation adjustment			(765	)			(1,690	)			77				(3,293	)
Changes in unrealized gains (losses) on short-term investments			470				(102	)			865				(1,384	)
Net change in other comprehensive income (loss)			(295	)			(1,792	)			942				(4,677	)
Comprehensive income (loss)		$	(23,774	)		$	79,716			$	(82,290	)		$	17,516
Net income (loss) per common share
Basic		$	(0.65	)		$	2.30			$	(2.32	)		$	0.63
Diluted		$	(0.65	)		$	2.22			$	(2.32	)		$	0.63
Weighted average shares used to compute    net income (loss) per share
Basic			36,142,255				35,402,086				35,882,826				35,265,193
Diluted			36,142,255				37,338,945				35,882,826				35,501,609

 

 

Page | 5

 

---

 

Nevro Corp.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

 

		September 30,				December 31,
		2023				2022
		(unaudited)
Assets
Current assets
Cash and cash equivalents		$	65,155			$	120,373
Short-term investments			255,103				254,012
Accounts receivable, net			68,984				78,930
Inventories, net			122,420				99,638
Prepaid expenses and other current assets			10,321				9,984
Total current assets			521,983				562,937
Property and equipment, net			24,031				22,271
Operating lease assets			10,099				13,430
Other assets			4,863				3,164
Restricted cash			606				606
Total assets		$	561,582			$	602,408
Liabilities and stockholders’ equity
Current liabilities
Accounts payable		$	28,854			$	26,849
Accrued liabilities and other			50,889				52,363
Total current liabilities			79,743				79,212
Long-term debt			187,803				186,867
Long-term operating lease liabilities			6,105				10,296
Other long-term liabilities			2,265				2,157
Total liabilities			275,916				278,532
Stockholders’ equity
Common stock, $0.001 par value, 290,000,000 shares authorized;   36,869,962 and 36,203,423 shares issued at September 30, 2023   and December 31, 2022, respectively; 36,187,046 and 35,520,507   shares outstanding at September 30, 2023 and December 31,   2022, respectively			36				35
Additional paid-in capital			978,211				934,132
Accumulated other comprehensive loss			(2,152	)			(3,094	)
Accumulated deficit			(690,429	)			(607,197	)
Total stockholders’ equity			285,666				323,876
Total liabilities and stockholders’ equity		$	561,582			$	602,408

 

Page | 6

 

---

 

Nevro Corp.

GAAP to Non-GAAP Adjusted EBITDA Reconciliation

(unaudited)

(in thousands)

 

The following table presents a reconciliation of GAAP net loss, as prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), to Adjusted EBITDA, a non-GAAP financial measure.

 

Reconciliation of actual results:

 

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
		(unaudited)								(unaudited)
GAAP Net Income (Loss)		$	(23,479	)		$	81,508			$	(83,232	)		$	22,193
Non-GAAP Adjustments:
Interest (income) expense, net			(1,976	)			480				(5,371	)			3,266
Provision for income taxes			130				485				932				907
Depreciation and amortization			1,723				1,642				5,016				4,780
Stock-based compensation expense			13,523				15,206				43,249				41,992
Certain litigation charges (credits)			—				(105,000	)			—				(105,000	)
Litigation-related expenses			4,284				1,884				12,972				9,513
Restructuring charges			—				—				373				—
Adjusted EBITDA		$	(5,795	)		$	(3,795	)		$	(26,061	)		$	(22,349	)

 

Reconciliation of guidance:

 

		Three Months Ended								Year Ended
		December 31, 2023								December 31, 2023
		(Low Case)				(High Case)				(Low Case)				(High Case)
GAAP Net Loss		$	(15,800	)		$	(14,800	)		$	(99,000	)		$	(98,000	)
Non-GAAP Adjustments			16,800				16,800				74,000				74,000
Adjusted EBITDA		$	1,000			$	2,000			$	(25,000	)		$	(24,000	)

 

Management uses certain non-GAAP financial measures, most specifically Adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives.

 

Management believes it is important to provide investors with the same non-GAAP metrics it uses to evaluate the performance and underlying trends of the Company's business operations to facilitate comparisons to its historical operating results and evaluate the effectiveness of its operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of the Company's underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

 

EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating non-GAAP Adjusted EBITDA, the Company further adjusts for the following items:

 

Page | 7

 

---

 

Full-year guidance excludes the impact of foreign currency fluctuations.

 

The non-GAAP financial measure should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP financial measures, as it is not prepared in accordance with U.S. GAAP.

 

Amounts may not add due to rounding.

 

The following table presents the reconciliation of net income (loss) used in computing basic and diluted net income (loss) per common share (in thousands):

 

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
Net income (loss) used in basic net income (loss) per    common share		$	(23,479	)		$	81,508			$	(83,232	)		$	22,193
Plus: Assumed conversions of dilutive convertible notes			—				1,305				—				—
Net income (loss) used in diluted net income (loss) per    common share		$	(23,479	)		$	82,813			$	(83,232	)		$	22,193

 

The following table presents the reconciliation of weighted average shares used in computing basic and diluted net income (loss) per common share:

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
Weighted average shares used to compute basic    net income (loss) per share			36,142,255				35,402,086				35,882,826				35,265,193
Plus effect of dilutive securities:
Stock-based awards from employee equity plans			—				129,718				—				236,416
Convertible senior notes			—				1,807,141				—				—
Weighted average shares used to compute    diluted net income (loss) per share			36,142,255				37,338,945				35,882,826				35,501,609

 

The following table presents the net income (loss) per common share - basic and diluted:

		Three Months Ended								Nine Months Ended September 30,
		September 30,								September 30,
		2023				2022				2023				2022
Net income (loss) per common share:
Basic		$	(0.65	)		$	2.30			$	(2.32	)		$	0.63
Diluted		$	(0.65	)		$	2.22			$	(2.32	)		$	0.63

 

###

Page | 8

 

---

v3.23.3

Document And Entity Information	Nov. 01, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 01, 2023
Entity Registrant Name	NEVRO CORP.
Entity Central Index Key	0001444380
Entity Emerging Growth Company	false
Securities Act File Number	001-36715
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-2568057
Entity Address, Address Line One	1800 Bridge Parkway
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	(650)
Local Phone Number	251-0005
Entity Information, Former Legal or Registered Name	N/A
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	NVRO
Security Exchange Name	NYSE

---